CDK4 and breast carcinoma: Levels of CDK4 and Cyclin D1, both of which are important molecular markers associated with cell-cycle progression, decreased following AG-205 treatment in both breast cancer cell lines (Fig. 2d and Supplementary Fig. 5a, b).